静脉-静脉体外膜氧合治疗的急性呼吸窘迫综合征患者碳氧血红蛋白与死亡率的U型关联
该回顾性队列研究纳入109例接受静脉-静脉ECMO治疗的ARDS患者,采用Cox比例风险模型分析碳氧血红蛋白百分比(COHb%)与死亡率的关联。结果显示COHb%低于3.25%时,每升高1单位死亡风险显著降低(HR 0.35;95%CI 0.15-0.80;p=0.013);高于3.25%时,每升高1单位死亡风险显著增加(HR 4.7;95%CI 1.5-14.7;p=0.007),呈非线性关联(p=0.006)。COHb%每升高1单位与脱离ECMO和机械通气的可能性降低、出院时间延长相关(均p<0.05)。COHb%与溶血显著相关,但与启动血液透析或输血无关。作者认为COHb%是ARDS-on-VV-ECMO患者死亡率的的新颖生物标志物,低COHb%患者可能从未来靶向抗氧化和抗炎通路的治疗(如低剂量吸入CO气体)中获益最多。
要点
- 在ARDS接受静脉-静脉ECMO的患者中,COHb%与死亡率呈U型关联(非线性p=0.006),拐点为3.25%。
- COHb%低于3.25%时,每升高1单位死亡风险显著降低(HR 0.35;95%CI 0.15-0.80;p=0.013)。
- COHb%高于3.25%时,每升高1单位死亡风险显著增加(HR 4.7;95%CI 1.5-14.7;p=0.007)。
- COHb%每升高1单位与脱离ECMO和机械通气的可能性降低、以及出院时间延长相关(均p<0.05)。
- COHb%与溶血显著相关,但与启动血液透析或输血无关。
适用人群与场景
- 纳入接受静脉-静脉体外膜氧合(ECMO)治疗的急性呼吸窘迫综合征(ARDS)患者。
- 研究场景为学术医疗中心ICU。
研究设计与关键结果
- 研究类型为回顾性队列研究,纳入109例连续患者。
- 采用Cox比例风险模型分析COHb%与死亡率的关联。
- COHb%低于3.25%时,每升高1单位死亡风险显著降低(HR 0.35;95%CI 0.15-0.80;p=0.013);高于3.25%时,每升高1单位死亡风险显著增加(HR 4.7;95%CI 1.5-14.7;p=0.007);非线性关联p=0.006。
- COHb%每升高1单位与脱离ECMO和机械通气的可能性降低、以及出院时间延长相关(均p<0.05)。
- COHb%与溶血显著相关,但与启动血液透析或输血无关。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,COHb%是ARDS-on-VV-ECMO患者死亡率的的新颖生物标志物,呈U型模式。
- 作者认为,CO过少(可能因宿主信号受损)或CO过多(可能因溶血)与较高死亡率相关。
- 作者认为,低COHb%患者可能从未来靶向抗氧化和抗炎通路的治疗(如低剂量吸入CO气体)中获益最多。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Carbon monoxide (CO) is an endogenous signaling molecule that activates cytoprotective programs implicated in the resolution of acute respiratory distress syndrome (ARDS) and survival of critical illness. Because CO levels can be measured in blood as carboxyhemoglobin, we hypothesized that carboxyhemoglobin percent (COHb%) may associate with mortality.
OBJECTIVES: To examine the relationship between COHb% and outcomes in patients with ARDS requiring venovenous extracorporeal membrane oxygenation (ECMO), a condition where elevated COHb% is commonly observed.
DESIGN: Retrospective cohort study.
SETTING: Academic medical center ICU.
PATIENTS: Patients were included that had ARDS on venovenous ECMO.
MEASUREMENTS AND MAIN RESULTS: We examined the association between COHb% and mortality using a Cox proportional hazards model. Secondary outcomes including ECMO duration, ventilator weaning, and hospital and ICU length of stay were examined using both subdistribution and causal-specific hazard models for competing risks. We identified 109 consecutive patients for analysis. Mortality significantly decreased per 1 U increase in COHb% below 3.25% (hazard ratio [HR], 0.35; 95% CI, 0.15-0.80; p = 0.013) and increased per 1 U increase above 3.25% (HR, 4.7; 95% CI, 1.5-14.7; p = 0.007) reflecting a nonlinear association (p = 0.006). Each unit increase in COHb% was associated with reduced likelihood of liberation from ECMO and mechanical ventilation, and increased time to hospital and ICU discharge (all p < 0.05). COHb% was significantly associated with hemolysis but not with initiation of hemodialysis or blood transfusions.
CONCLUSIONS: In patients with ARDS on venovenous ECMO, COHb% is a novel biomarker for mortality exhibiting a U-shaped pattern. Our findings suggest that too little CO (perhaps due to impaired host signaling) or excess CO (perhaps due to hemolysis) is associated with higher mortality. Patients with low COHb% may exhibit the most benefit from future therapies targeting anti-oxidant and anti-inflammatory pathways such as low-dose inhaled CO gas.
参考来源
- Meservey A, Krishnan G, Green CL, et al. U-Shaped Association Between Carboxyhemoglobin and Mortality in Patients With Acute Respiratory Distress Syndrome on Venovenous Extracorporeal Membrane Oxygenation. Crit Care Explor. 2023. PMID: 37614802. doi:10.1097/CCE.0000000000000957
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。